

HIGHLIGHTS OF PRESCRIBING INFORMATION

These highlights do not include all the information needed to use ONGLYZA safely and effectively. See full prescribing information for ONGLYZA.

ONGLYZA® (saxagliptin) tablets, for oral use

Initial U.S. Approval: 2009

RECENT MAJOR CHANGES

Warnings and Precautions

Pancreatitis (5.1)	4/2016
Heart Failure (5.2)	4/2016
Bullous Pemphigoid (5.6)	1/2017

INDICATIONS AND USAGE

ONGLYZA is a dipeptidyl peptidase-4 (DPP4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. (1.1, 14)

Limitation of use:

- Not used for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis. (1.2)

DOSAGE AND ADMINISTRATION

- Recommended dosage is 2.5 mg or 5 mg once daily taken regardless of meals. (2.1)
- Patients with moderate or severe renal impairment, or end-stage renal disease (CrCl ≤50 mL/min): Recommended dosage is 2.5 mg once daily regardless of meals. (2.2)
- Assess renal function before starting ONGLYZA and periodically thereafter. (2.2)
- 2.5 mg daily is recommended for patients also taking strong cytochrome P450 3A4/5 (CYP3A4/5) inhibitors (e.g., ketoconazole). (2.3, 7.1)

DOSAGE FORMS AND STRENGTHS

- Tablets: 5 mg and 2.5 mg. (3)

CONTRAINDICATIONS

- History of a serious hypersensitivity reaction (e.g., anaphylaxis, angioedema, exfoliative skin conditions) to ONGLYZA. (4)

WARNINGS AND PRECAUTIONS

- Pancreatitis:** If pancreatitis is suspected, promptly discontinue ONGLYZA. (5.1)
- Heart Failure:** Consider the risks and benefits of ONGLYZA in patients who have known risk factors for heart failure. Monitor patients for signs and symptoms. (5.2)

- Hypoglycemia:** In add-on to sulfonylurea, add-on to insulin, and add-on to metformin plus sulfonylurea trials, confirmed hypoglycemia was more common in patients treated with ONGLYZA compared to placebo. When used with an insulin secretagogue (e.g., sulfonylurea) or insulin, a lower dose of insulin secretagogue or insulin may be required to minimize the risk of hypoglycemia. (5.3, 6.1)
- Hypersensitivity-Related Events (e.g., urticaria, facial edema):** More common in patients treated with ONGLYZA than in patients treated with placebo; and postmarketing reports of serious hypersensitivity reactions such as anaphylaxis, angioedema, and exfoliative skin conditions. Promptly discontinue ONGLYZA, assess for other potential causes, institute appropriate monitoring and treatment, and initiate alternative treatment for diabetes. (5.4, 6.1, 6.2)
- Arthralgia:** Severe and disabling arthralgia has been reported in patients taking DPP4 inhibitors. Consider as a possible cause for severe joint pain and discontinue drug if appropriate. (5.5)
- Bullous Pemphigoid:** There have been postmarketing reports of bullous pemphigoid requiring hospitalization in patients taking DPP-4 inhibitors. Tell patients to report development of blisters or erosions. If bullous pemphigoid is suspected, discontinue ONGLYZA. (5.6)
- Macrovascular Outcomes:** There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with ONGLYZA or any other antidiabetic drug. (5.7)

ADVERSE REACTIONS

- Adverse reactions reported in ≥5% of patients treated with ONGLYZA and more commonly than in patients treated with placebo are upper respiratory tract infection, urinary tract infection, and headache. (6.1)
- Peripheral edema was reported more commonly in patients treated with the combination of ONGLYZA and a thiazolidinedione (TZD) than in patients treated with the combination of placebo and TZD. (6.1)

To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca at 1-800-236-9933 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DRUG INTERACTIONS

- Strong CYP3A4/5 inhibitors (e.g., ketoconazole):** Coadministration with ONGLYZA significantly increases saxagliptin concentrations. Recommend limiting ONGLYZA dosage to 2.5 mg once daily. (2.3, 7.1)

USE IN SPECIFIC POPULATIONS

- No adequate and well-controlled studies in pregnant women. (8.1)

See 17 for PATIENT COUNSELING INFORMATION and Medication Guide

Revised: 1/2017

FULL PRESCRIBING INFORMATION: CONTENTS*

[1 INDICATIONS AND USAGE](#)

- [1.1 Monotherapy and Combination Therapy](#)
- [1.2 Limitation of Use](#)

[2 DOSAGE AND ADMINISTRATION](#)

- [2.1 Recommended Dosage](#)
- [2.2 Dosage in Patients with Renal Impairment](#)
- [2.3 Dosage Adjustment with Concomitant Use of Strong CYP3A4/5 Inhibitors](#)
- [2.4 Concomitant Use with an Insulin Secretagogue \(e.g., Sulfonylurea\) or with Insulin](#)

[3 DOSAGE FORMS AND STRENGTHS](#)

[4 CONTRAINDICATIONS](#)

[5 WARNINGS AND PRECAUTIONS](#)

- [5.1 Pancreatitis](#)
- [5.2 Heart Failure](#)
- [5.3 Hypoglycemia with Concomitant Use of Sulfonylurea or Insulin](#)
- [5.4 Hypersensitivity Reactions](#)
- [5.5 Severe and Disabling Arthralgia](#)
- [5.6 Bullous Pemphigoid](#)
- [5.7 Macrovascular Outcomes](#)

[6 ADVERSE REACTIONS](#)

- [6.1 Clinical Trials Experience](#)
- [6.2 Postmarketing Experience](#)

[7 DRUG INTERACTIONS](#)

- [7.1 Strong Inhibitors of CYP3A4/5 Enzymes](#)

[8 USE IN SPECIFIC POPULATIONS](#)

- [8.1 Pregnancy](#)
- [8.3 Nursing Mothers](#)
- [8.4 Pediatric Use](#)
- [8.5 Geriatric Use](#)

[10 OVERDOSAGE](#)

[11 DESCRIPTION](#)

[12 CLINICAL PHARMACOLOGY](#)

- [12.1 Mechanism of Action](#)
- [12.2 Pharmacodynamics](#)
- [12.3 Pharmacokinetics](#)

[13 NONCLINICAL TOXICOLOGY](#)

- [13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility](#)
- [13.2 Animal Toxicology and/or Pharmacology](#)

[14 CLINICAL STUDIES](#)

- [14.1 Glycemic Efficacy Trials](#)
- [14.2 Renal Impairment](#)
- [14.3 Cardiovascular Safety Trial](#)

[16 HOW SUPPLIED/STORAGE AND HANDLING](#)

[17 PATIENT COUNSELING INFORMATION](#)

*Sections or subsections omitted from the full prescribing information are not listed.

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

1.1 Monotherapy and Combination Therapy

ONGLYZA is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [see [Clinical Studies \(14\)](#)].

1.2 Limitation of Use

ONGLYZA is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis, as it would not be effective in these settings.

2 DOSAGE AND ADMINISTRATION

2.1 Recommended Dosage

The recommended dosage of ONGLYZA is 2.5 mg or 5 mg once daily taken regardless of meals. ONGLYZA tablets must not be split or cut.

2.2 Dosage in Patients with Renal Impairment

No dosage adjustment for ONGLYZA is recommended for patients with mild renal impairment (creatinine clearance [CrCl] >50 mL/min).

The dosage of ONGLYZA is 2.5 mg once daily (regardless of meals) for patients with moderate or severe renal impairment, or with end-stage renal disease (ESRD) requiring hemodialysis (creatinine clearance [CrCl] ≤50 mL/min) [see [Clinical Pharmacology \(12.3\)](#) and [Clinical Studies \(14.2\)](#)]. ONGLYZA should be administered following hemodialysis. ONGLYZA has not been studied in patients undergoing peritoneal dialysis.

Because the dosage of ONGLYZA should be limited to 2.5 mg based upon renal function, assessment of renal function is recommended prior to initiation of ONGLYZA and periodically thereafter. Renal function can be estimated from serum creatinine using the Cockcroft-Gault formula or Modification of Diet in Renal Disease formula [see [Clinical Pharmacology \(12.3\)](#)].

2.3 Dosage Adjustment with Concomitant Use of Strong CYP3A4/5 Inhibitors

The dosage of ONGLYZA is 2.5 mg once daily when coadministered with strong cytochrome P450 3A4/5 (CYP3A4/5) inhibitors (e.g., ketoconazole, atazanavir, clarithromycin, indinavir, itraconazole, nefazodone, nelfinavir, ritonavir, saquinavir, and telithromycin) [see [Drug Interactions \(7.1\)](#) and [Clinical Pharmacology \(12.3\)](#)].

2.4 Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin

When ONGLYZA is used in combination with an insulin secretagogue (e.g., sulfonylurea) or with insulin, a lower dose of the insulin secretagogue or insulin may be required to minimize the risk of hypoglycemia [see [Warnings and Precautions \(5.3\)](#)].

3 DOSAGE FORMS AND STRENGTHS

- ONGLYZA (saxagliptin) 5 mg tablets are pink, biconvex, round, film-coated tablets with “5” printed on one side and “4215” printed on the reverse side, in blue ink.
- ONGLYZA (saxagliptin) 2.5 mg tablets are pale yellow to light yellow, biconvex, round, film-coated tablets with “2.5” printed on one side and “4214” printed on the reverse side, in blue ink.

4 CONTRAINDICATIONS

ONGLYZA is contraindicated in patients with a history of a serious hypersensitivity reaction to ONGLYZA, such as anaphylaxis, angioedema, or exfoliative skin conditions [*see [Warnings and Precautions \(5.4\)](#) and [Adverse Reactions \(6.2\)](#)*].

5 WARNINGS AND PRECAUTIONS

5.1 Pancreatitis

There have been postmarketing reports of acute pancreatitis in patients taking ONGLYZA. In a cardiovascular outcomes trial enrolling participants with established atherosclerotic cardiovascular disease (ASCVD) or multiple risk factors for ASCVD (SAVOR trial), cases of definite acute pancreatitis were confirmed in 17 of 8240 (0.2%) patients receiving ONGLYZA compared to 9 of 8173 (0.1%) receiving placebo. Preexisting risk factors for pancreatitis were identified in 88% (15/17) of those patients receiving ONGLYZA and in 100% (9/9) of those patients receiving placebo.

After initiation of ONGLYZA, observe patients for signs and symptoms of pancreatitis. If pancreatitis is suspected, promptly discontinue ONGLYZA and initiate appropriate management. It is unknown whether patients with a history of pancreatitis are at increased risk for the development of pancreatitis while using ONGLYZA.

5.2 Heart Failure

In a cardiovascular outcomes trial enrolling participants with established ASCVD or multiple risk factors for ASCVD (SAVOR trial), more patients randomized to ONGLYZA (289/8280, 3.5%) were hospitalized for heart failure compared to patients randomized to placebo (228/8212, 2.8%). In a time-to-first-event analysis the risk of hospitalization for heart failure was higher in the ONGLYZA group (estimated Hazard Ratio: 1.27; 95% CI: 1.07, 1.51). Subjects with a prior history of heart failure and subjects with renal impairment had a higher risk for hospitalization for heart failure, irrespective of treatment assignment.

Consider the risks and benefits of ONGLYZA prior to initiating treatment in patients at a higher risk for heart failure. Observe patients for signs and symptoms of heart failure during therapy. Advise patients of the characteristic symptoms of heart failure and to immediately report such symptoms. If heart failure develops, evaluate and manage according to current standards of care and consider discontinuation of ONGLYZA.

5.3 Hypoglycemia with Concomitant Use of Sulfonylurea or Insulin

When ONGLYZA was used in combination with a sulfonylurea or with insulin, medications known to cause hypoglycemia, the incidence of confirmed hypoglycemia was increased over that of placebo used in combination with a sulfonylurea or with insulin [*see [Adverse Reactions \(6.1\)](#)*]. Therefore, a lower dose of the insulin secretagogue or insulin may be required to minimize the risk of hypoglycemia when used in combination with ONGLYZA [*see [Dosage and Administration \(2.4\)](#)*].

5.4 Hypersensitivity Reactions

There have been postmarketing reports of serious hypersensitivity reactions in patients treated with ONGLYZA. These reactions include anaphylaxis, angioedema, and exfoliative skin conditions. Onset of these reactions occurred within the first 3 months after initiation of treatment with ONGLYZA, with some reports occurring after the first dose.

If a serious hypersensitivity reaction is suspected, discontinue ONGLYZA, assess for other potential causes for the event, and institute alternative treatment for diabetes [see [Adverse Reactions \(6.2\)](#)].

Use caution in a patient with a history of angioedema to another dipeptidyl peptidase-4 (DPP4) inhibitor because it is unknown whether such patients will be predisposed to angioedema with ONGLYZA.

5.5 Severe and Disabling Arthralgia

There have been postmarketing reports of severe and disabling arthralgia in patients taking DPP4 inhibitors. The time to onset of symptoms following initiation of drug therapy varied from one day to years. Patients experienced relief of symptoms upon discontinuation of the medication. A subset of patients experienced a recurrence of symptoms when restarting the same drug or a different DPP4 inhibitor. Consider DPP4 inhibitors as a possible cause for severe joint pain and discontinue drug if appropriate.

5.6 Bullous Pemphigoid

Postmarketing cases of bullous pemphigoid requiring hospitalization have been reported with DPP-4 inhibitor use. In reported cases, patients typically recovered with topical or systemic immunosuppressive treatment and discontinuation of the DPP-4 inhibitor. Tell patients to report development of blisters or erosions while receiving ONGLYZA. If bullous pemphigoid is suspected, ONGLYZA should be discontinued and referral to a dermatologist should be considered for diagnosis and appropriate treatment.

5.7 Macrovascular Outcomes

There have been no clinical studies establishing conclusive evidence of macrovascular risk reduction with ONGLYZA or any other antidiabetic drug.

6 ADVERSE REACTIONS

The following serious adverse reactions are described below or elsewhere in the prescribing information:

- Pancreatitis [see [Warnings and Precautions \(5.1\)](#)]
- Heart Failure [see [Warnings and Precautions \(5.2\)](#)]
- Hypoglycemia with Concomitant Use of Sulfonylurea or Insulin [see [Warnings and Precautions \(5.3\)](#)]
- Hypersensitivity Reactions [see [Warnings and Precautions \(5.4\)](#)]
- Severe and disabling arthralgia [see [Warnings and Precautions \(5.5\)](#)]
- Bullous pemphigoid [see [Warnings and Precautions \(5.6\)](#)]

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Adverse Reactions in Efficacy Trials

The data in Table 1 are derived from a pool of 5 placebo-controlled clinical trials [see [Clinical Studies \(14\)](#)]. These data shown in the table reflect exposure of 882 patients to ONGLYZA and a mean duration of exposure to ONGLYZA of 21 weeks. The mean age of these patients was 55 years, 1.4 % were 75 years or older and 48.4% were male. The population was 67.5% White, 4.6% Black or African American, 17.4% Asian, Other 10.5% and 9.8% were of Hispanic or Latino ethnicity. At baseline the population had diabetes for an average of 5.2 years and a mean HbA1c of 8.2%. Baseline estimated renal function was normal or mildly impaired (eGFR \geq 60mL/min/1.73m²) in 91% of these patients.

Table 1 shows common adverse reactions, excluding hypoglycemia, associated with the use of ONGLYZA. These adverse reactions occurred more commonly on ONGLYZA than on placebo and occurred in at least 5% of patients treated with ONGLYZA.

Table 1: Adverse Reactions in Placebo-Controlled Trials* Reported in \geq 5% of Patients Treated with ONGLYZA 5 mg and More Commonly than in Patients Treated with Placebo

	% of Patients	
	ONGLYZA 5 mg N=882	Placebo N=799
Upper respiratory tract infection	7.7	7.6
Urinary tract infection	6.8	6.1
Headache	6.5	5.9

* The 5 placebo-controlled trials include two monotherapy trials and one add-on combination therapy trial with each of the following: metformin, thiazolidinedione, or glyburide. Table shows 24-week data regardless of glycemic rescue.

In patients treated with ONGLYZA 2.5 mg, headache (6.5%) was the only adverse reaction reported at a rate \geq 5% and more commonly than in patients treated with placebo.

In the add-on to TZD trial, the incidence of peripheral edema was higher for ONGLYZA 5 mg versus placebo (8.1% and 4.3%, respectively). The incidence of peripheral edema for ONGLYZA 2.5 mg was 3.1%. None of the reported adverse reactions of peripheral edema resulted in study drug discontinuation. Rates of peripheral edema for ONGLYZA 2.5 mg and ONGLYZA 5 mg versus placebo were 3.6% and 2% versus 3% given as monotherapy, 2.1% and 2.1% versus 2.2% given as add-on therapy to metformin, and 2.4% and 1.2% versus 2.2% given as add-on therapy to glyburide.

The incidence rate of fractures was 1.0 and 0.6 per 100 patient-years, respectively, for ONGLYZA (pooled analysis of 2.5 mg, 5 mg, and 10 mg) and placebo. The 10 mg dosage is not an approved dosage. The incidence rate of fracture events in patients who received ONGLYZA did not increase over time. Causality has not been established and nonclinical studies have not demonstrated adverse effects of ONGLYZA on bone.

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.